Clinical Research Focus. 51st Edition

AI Clinical Trial Budget Calculator from Cromos Pharma

Planning a clinical trial budget early can be slow and uncertain. Cromos Pharma AI powered calculator helps you quickly model countries, sites, enrollment, and study design and instantly see how each factor impacts cost. Compare scenarios and generate a clear, board ready overview in minutes, supporting faster and more informed decisions before full feasibility.

Learn more

The Shift to Human Based Drug Development Is Accelerating

Regulators and research leaders are moving in the same direction. The FDA has released new guidance supporting alternatives to animal testing, while the NIH has committed $150 million to scale human based research methods, including organ on chip, in vitro systems, and AI driven models. Together, these signals point to a clear shift toward more predictive, human relevant data in early development. For sponsors, this means faster decision making, improved clinical translation, and a growing need to rethink traditional preclinical strategies.

Learn more

 

Kidney Day 2026 | What Sponsors Should Know About the Future of Kidney Trials

Kidney disease is rapidly moving into focus, with growing pipelines, new regulatory momentum, and increasing complexity in trial design. This article explores key trends shaping nephrology trials, from evolving endpoints and patient recruitment challenges to emerging opportunities in cardio renal and rare kidney diseases.

Learn more

EMA Expands PRIME to Speed Up Drug Development in the EU

The European Medicines Agency has introduced new PRIME tools to improve scientific dialogue and support developers throughout the drug development process. With faster advice, clearer planning, and earlier readiness checks, sponsors can better anticipate risks and stay on track toward approval in the EU.

Learn more

FDA Signals Shift in Regulatory Approach to Autoimmune CAR-T

Autoimmune CAR-T is moving beyond early breakthroughs and starting to shape a new treatment paradigm. Recent signals from the FDA suggest a more flexible, case by case regulatory path, but with clear expectations around long term safety and durability of response. The big question now is whether these therapies can deliver lasting remission and how sponsors should prepare for what comes next.

Learn more

AI Is Moving Upstream in Trial Design

Bristol Myers Squibb has partnered with Faro to apply AI to clinical trial protocol design. By improving protocol quality early, sponsors can reduce amendments, accelerate timelines, and increase trial efficiency. This reflects a broader shift toward smarter, data-driven trial planning.

Learn more

Phase 3 Success Expands Targeted Therapy in Rare Immunologic Disease

Benralizumab significantly reduced flare risk in patients with hypereosinophilic syndrome in a phase 3 trial. The results highlight the growing role of targeted biologics in rare immune disorders and reinforce the potential of eosinophil-driven pathways as therapeutic targets.

Learn more

Blackstone Closes Record $6.3B Life Sciences Fund

Blackstone has raised a record $6.3 billion for its latest life sciences fund, highlighting strong investor confidence in biotech and clinical development. With a focus on late-stage assets, the fund is expected to accelerate the advancement of high-potential therapies and support continued momentum across global clinical pipelines.

Learn more

 

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us

OUR PUBLICATIONS